Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
If the drug company Tremeau Pharmaceuticals does obtain permission to resurrect Vioxx (rofecoxib) for the relief of severe joint pain caused by Hamophilia, increased cardiovascular risk should be the least of its worries. Other seemingly unanticipated side effects will be of more importance including death from cerebral and gastrointestinal haemorrhage and disability from epistaxes, urinary bleeding and haemarthroses. It is possibly an outcome not even considered by the drug company that the Vioxx, used to treat the pain from haemarthroses due to Haemophilia, may actually produce haemarthroses. If some of the drug company executives are considering travelling to Britain for the wedding in May, they should know that anyone who promotes the use of a non steroidal ant-inflammatory drug as an analgesic in someone with severe Haemophilia risks being put in the Tower of London. J.L.Raven
No competing interests
04 March 2018
John L Raven
77 View Terrace. East Fremantle, WA 6158, Australia